Downstream formulation for this bisquaternary tetrahydroisoquinoline dioxalate in operating-room anesthesia begins with a sterile, ready-to-use aqueous injection rather than an oral solid dosage form. The bisquaternary structure produces a high-permeability barrier across the intestinal epithelium, so tablet, capsule, and granule presentations are not industrial formulation targets for this API; any request for an oral grade is rejected at pre-formulation screening because the permanent cationic charge prevents reproducible systemic absorption. The primary commercial presentation is therefore a single-dose, preservative-free parenteral solution filled into Type I borosilicate glass vials. A representative formulation at 2 mg/mL active concentration, expressed as the cationic moiety, is prepared by dissolving the dioxalate salt in Water for Injection that has been nitrogen-sparged to reduce dissolved oxygen below 0.5 mg/L. The pH is adjusted with dilute hydrochloric acid or sodium hydroxide to 3.0–3.7, because the Hofmann elimination rate of the bisquaternary tetrahydroisoquinoline framework increases sharply above pH 5.0 and is suppressed in the acidic range. The osmolality is adjusted with sodium chloride to 280–300 mOsmol/kg to avoid intravenous injection pain and hemolysis. The solution is prefiltered through a 0.45 μm clarifying membrane and then sterile-filtered through a 0.22 μm PVDF or PES membrane with validated bubble point and diffusion test parameters. Filling is performed under nitrogen overlay on an aseptic filling line with a residual oxygen target below 2% in vial headspace. Terminal steam sterilization is excluded because exposure to 121°C for 15 minutes accelerates Hofmann elimination and ester hydrolysis beyond acceptable shelf-life limits for a parenteral product. Compliance for the finished solution falls under FDA 21 CFR 210 and 21 CFR 211, EU GMP Annex 1 2022 for sterile products, USP <1> for injections, USP <71> for sterility, USP <85> for bacterial endotoxins, USP <788> for subvisible particulate matter, USP <790> for visible particulates, and ICH Q3D(R2) for elemental impurities. The terminal presentations are 5 mL, 10 mL, and 20 mL single-dose vials at 2 mg/mL and 10 mg/mL, with the 10 mg/mL presentation reserved for dilution before infusion. Batch-to-batch variance on production-scale lines is commonly observed in residual oxygen and pH drift during hold times; therefore the compounding vessel is jacketed and held at 2–8°C, and the maximum holding time after pH adjustment is controlled by in-process pH, assay, and impurity checks.

What Limits Dilution Stability in Lactated Ringer’s and Other Alkaline Infusion Media?

For continuous neuromuscular blockade in the intensive care unit, the 10 mg/mL concentrate is diluted to a target range of 0.1–2.0 mg/mL with 0.9% sodium chloride injection or 5% dextrose injection. The dilution ratio is not fixed solely by dose; it is constrained by the pH-dependent Hofmann elimination and ester hydrolysis pathways of the bisquaternary tetrahydroisoquinoline nucleus. Lactated Ringer’s injection, sodium bicarbonate, and most alkaline parenteral fluids raise the admixture pH above 5.5, at which the degradation rate accelerates to a level that can reduce active concentration by more than 10% within a few hours at room temperature. Published data for the dioxalate salt in this specific admixture configuration are limited; conservative in-use protocols therefore adopt stability boundaries established for the corresponding besylate salt, which require a final pH below 5.0 and storage at 2–8°C when extended hold times are required. Compounding is conducted inside an ISO Class 5 laminar airflow workbench or barrier isolator following USP <797> standards for medium-risk compounded sterile preparations. The pharmacist adds the concentrate through a closed-system transfer device into a sterile non-PVC, DEHP-free ethylene-vinyl acetate or polyolefin infusion bag. The finished admixture is labelled with a beyond-use date of 24 hours when stored at 2–8°C and is not subjected to heat sterilization. Terminal product types include 50 mL, 100 mL, and 250 mL ready-to-administer infusion bags, as well as 20 mL to 60 mL polypropylene syringe-pump reservoirs filled to a concentration of 0.2 mg/mL or 0.5 mg/mL for weight-based infusion. Administration sets must be low-sorption and free of DEHP; Luer connectors should follow ISO 80369-7:2016 to prevent misconnection. The primary incompatibility boundary is not the drug concentration but the admixture pH and the presence of nucleophilic buffers; therefore in-process pH measurement before and after dilution is mandatory.

The aseptic fill-finish line for oxygen-sensitive bisquaternary dioxalate solutions is configured around a closed barrier isolator with a unidirectional airflow velocity of 0.36–0.54 m/s at the fill point and an air cleanliness classification of ISO 5 in the critical zone. The line operates with a 100% in-line checkweigher and a high-voltage leak detection station; each vial is inspected after capping for visible particulates according to USP <790> and sampled for USP <788> subvisible particulate counts. The container-closure system consists of Type I borosilicate glass vials, 20 mm bromobutyl stoppers, and aluminum flip-off overseals; the stopper moisture specification is set below 0.5% to avoid pH drift. The headspace oxygen limit is controlled below 2% by nitrogen flushing before stoppering; a residual oxygen analyzer with a zirconium oxide sensor is used for process verification. The formulation addition ratio remains at 2 mg/mL or 10 mg/mL active concentration, with no antioxidant or preservative added because the acidic pH and nitrogen overlay are sufficient to limit oxidative degradation during shelf-life. If a batch is held before sterile filtration beyond 8 hours at 2–8°C, in-process assay and pH are retested, and the batch is released only when the pH remains within 3.0–3.7 and individual impurities do not exceed specification. Container closure integrity testing follows USP <1207> using dye ingress, vacuum decay, or helium leak method; seal strength is monitored by ASTM F88 and ASTM F2096 methods. The finished terminal presentations are single-dose capped vials with tamper-evident overseals, labelled for intravenous administration, and packed in cartons with a temperature indicator for cold-chain distribution. The line is cleaned and sterilized with vaporized hydrogen peroxide in the isolator; product-contact parts are 316L stainless steel, PTFE, and silicone tubing, and the filling needle is verified for particulates before each campaign.

Cold-Chain Distribution and Thermal Excursion Limits for Refrigerated Vials

Distribution of the finished injectable vials is confined to a 2–8°C cold chain because the bisquaternary tetrahydroisoquinoline nucleus undergoes both Hofmann elimination and ester hydrolysis at rates that are strongly temperature-dependent. The formulation addition ratio is not modified for distribution; no freeze-protectant or additional buffering excipient is introduced, so the vial is identical to the fill-finish presentation. Thermal stability protocols follow ICH Q1A(R2) for storage conditions and USP <1079> for good storage and distribution practices; shipping qualification includes summer and winter lane temperature mapping with calibrated data loggers placed at the center and edge of each pallet. Freezing is a hard rejection condition because ice crystallization can concentrate the drug and cause pH shift, leading to precipitation or dimer formation upon thawing. If a thermal excursion exceeds 8°C but remains below 25°C for less than 24 hours, a stability review is performed using existing accelerated data; excursions above 25°C or repeated freeze-thaw cycles result in quarantine and batch disposition. The terminal product in this segment remains the single-dose vial, but the distribution-specific output is the cold-chain-qualified, temperature-monitored unit load. A temperature indicator strip affixed to the carton provides a visual threshold check at 8°C and 25°C. The production process includes packing under refrigerated conditions, cold-room staging, and loading into actively refrigerated vehicles with continuous temperature recording. Because there is no terminal sterilization step, vial closure integrity must be confirmed after shipping using USP <1207> vacuum decay; any increase in leak rate above the validation threshold is treated as a critical deviation.

When a Hospital Pharmacy Compounds Patient-Specific Infusion Syringes Under USP <797>

At the hospital pharmacy level, the 2 mg/mL or 10 mg/mL vial is transferred into patient-specific syringes for syringe-pump administration in the operating room, the post-anesthesia care unit, or the intensive care unit. The addition ratio for this downstream segment is derived from the prescribed µg/kg/min infusion rate; a common starting dilution is 0.2 mg/mL or 0.5 mg/mL in 0.9% sodium chloride injection, prepared by transferring 10 mg of active moiety into a 50 mL syringe. Compounding is performed in an ISO Class 5 laminar airflow workbench inside an ISO Class 7 buffer area under the requirements of USP <797>; the final syringe is labelled with patient identifier, drug concentration, diluent, and beyond-use date. The production process requires a closed-system transfer device to minimize aerosol and contamination, and the syringe is fitted with a Luer-lock connector compliant with ISO 80369-7:2016 to prevent inadvertent connection to epidural or enteral lines. The terminal product types are 20 mL, 30 mL, and 50 mL polypropylene Luer-lock syringes for syringe pumps, as well as 10 mL bolus syringes for anesthesia induction when vial access is impractical. The dioxalate salt must not be mixed in the same syringe with thiopental sodium or any alkaline induction agent because the resultant pH shift above 5.0 triggers rapid Hofmann elimination and visible precipitation. The bisquaternary ammonium structure may exhibit low surface sorption to polypropylene at dilute concentrations; therefore the compounding protocol requires a priming volume to be discarded before dose delivery to avoid subtherapeutic delivery from syringe wall adsorption.